Bio-Rad and 10X Genomics end patent fight with new licensing deal

Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

10x Genomics strikes back in Bio-Rad saga with USITC ban

13 February 2020 US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.

Big Pharma

Bio-Rad asks for review of DNA patent ruling

17 June 2021 Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

Big Pharma

PeriRx’s breach of licensing contract suit can’t prevail

13 January 2022 Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.

More on this story

Americas

10x Genomics strikes back in Bio-Rad saga with USITC ban

13 February 2020 US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.

Big Pharma

Bio-Rad asks for review of DNA patent ruling

17 June 2021 Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

Big Pharma

PeriRx’s breach of licensing contract suit can’t prevail

More on this story

Americas

10x Genomics strikes back in Bio-Rad saga with USITC ban

13 February 2020 US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.

Big Pharma

Bio-Rad asks for review of DNA patent ruling

17 June 2021 Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

Big Pharma

PeriRx’s breach of licensing contract suit can’t prevail